Detalhe da pesquisa
1.
Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients.
Ann Saudi Med
; 44(2): 93-103, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38615184